Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863462 | 0.98 | KMT2A (0.45) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL7870352 | 0.97 | ALDH1A1 (0.45) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL7863477 | 0.97 | ALDH1A1 (0.45) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL7871561 | 0.87 | ALDH1A1 (0.36) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL7863478 | 0.77 | ALDH1A1 (0.48) | KMT2ASMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL7871625 | 0.76 | TDP1 (0.38) | ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL7870301 | 0.75 | TDP1 (0.38) | ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL7871546 | 0.74 | TDP1 (0.41) | ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL7871692 | 0.74 | MEN1 (0.37) | KMT2AALDH1A1 | |
| SCHEMBL7872436 | 0.74 | ALDH1A1 (0.44) | SMN1; SMN2KDM4EALDH1A1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | TAKATANI MUNEO (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6251905-B1 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0771319-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996002542-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | PDGFA, HGF, REN | KMT2A 971/4885SMN1; SMN2 4706/4885KDM4E 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.